Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Daar

Showing results (121-130 of 222) with videos related to

Pageof 23
Sort By:
AIDS (London, England)|October 3, 2023
Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammationMalini M Gandhi, Kim-Lien Nguyen, Jordan E Lake, et al.
Journal of Clinical and Translational Science|January 30, 2023
A community-partnered approach for diversity in COVID-19 vaccine clinical trialsYelba Castellon-Lopez, Raphael Landovitz, Ejiro Ntekume, et al.
Therapeutic Drug Monitoring|November 15, 2017
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive ParticipantsCindy J Bednasz, Charles S Venuto, Qing Ma, et al.
AIDS (London, England)|February 28, 2024
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infectionLaurie A VanderVeen, Lisa Selzer, Brian Moldt, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2019
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202Cindy J Bednasz, Charles S Venuto, Qing Ma, et al.
Journal of Virology|May 3, 2014
Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatmentSara Gianella, Marta Massanella, Douglas D Richman, et al.
AIDS (London, England)|October 21, 2006
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacityJason D Barbour, Frederick M Hecht, Susan J Little, et al.
Pharmacogenetics and Genomics|May 31, 2018
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse eventsDavid W Haas, Yuki Bradford, Anurag Verma, et al.
Pharmacogenetics and Genomics|October 20, 2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEmily R Holzinger, Benjamin Grady, Marylyn D Ritchie, et al.
The Journal of Infectious Diseases|April 6, 2005
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1Matthew C Strain, Susan J Little, Eric S Daar, et al.
Pageof 23

Showing results (121-130 of 222) with videos related to

Sort By:
Pageof 23
AIDS (London, England)|October 3, 2023
Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammationMalini M Gandhi, Kim-Lien Nguyen, Jordan E Lake, et al.
Journal of Clinical and Translational Science|January 30, 2023
A community-partnered approach for diversity in COVID-19 vaccine clinical trialsYelba Castellon-Lopez, Raphael Landovitz, Ejiro Ntekume, et al.
Therapeutic Drug Monitoring|November 15, 2017
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive ParticipantsCindy J Bednasz, Charles S Venuto, Qing Ma, et al.
AIDS (London, England)|February 28, 2024
HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infectionLaurie A VanderVeen, Lisa Selzer, Brian Moldt, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2019
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202Cindy J Bednasz, Charles S Venuto, Qing Ma, et al.
Journal of Virology|May 3, 2014
Cytomegalovirus replication in semen is associated with higher levels of proviral HIV DNA and CD4+ T cell activation during antiretroviral treatmentSara Gianella, Marta Massanella, Douglas D Richman, et al.
AIDS (London, England)|October 21, 2006
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacityJason D Barbour, Frederick M Hecht, Susan J Little, et al.
Pharmacogenetics and Genomics|May 31, 2018
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse eventsDavid W Haas, Yuki Bradford, Anurag Verma, et al.
Pharmacogenetics and Genomics|October 20, 2012
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEmily R Holzinger, Benjamin Grady, Marylyn D Ritchie, et al.
The Journal of Infectious Diseases|April 6, 2005
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1Matthew C Strain, Susan J Little, Eric S Daar, et al.
Pageof 23